PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1684420
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1684420
Rapid Influenza Diagnostic Tests Market size was valued at USD 1,396.78 Million in 2024, expanding to a CAGR of 5.2% from 2025 to 2032.
Rapid Influenza Diagnostic Tests (RIDTs) are quick tests used to detect influenza (flu) viruses in respiratory specimens. These tests can provide results within 10-15 minutes and are commonly used in clinics, hospitals, and doctor's offices to help diagnose flu infections.
Rapid Influenza Diagnostic Tests Market- Market Dynamics
The increasing prevalence of influenzas & respiratory diseases and the need for POC testing is expected to propel market demand
One of the primary factors driving the growth of the rapid influenza diagnostic tests market is the increasing incidence of seasonal influenza outbreaks worldwide. According to the World Health Organization (WHO), influenza affects millions of people annually, leading to severe complications, hospitalizations, and deaths, particularly among high-risk populations such as children, the elderly, and individuals with chronic illnesses. The COVID-19 pandemic has also heightened concerns about respiratory infections, leading to increased demand for rapid diagnostic solutions to differentiate between influenza and other viral diseases. Campaigns by organizations like the Centers for Disease Control and Prevention (CDC) and WHO encourage timely testing and vaccination, thereby boosting the demand for RIDTs. Additionally, initiatives for universal healthcare coverage and improved access to diagnostic facilities in developing countries are further driving market growth.
The shift towards point-of-care (POC) testing is a significant market driver, as healthcare providers and patients seek faster, more accessible, and cost-effective diagnostic solutions. RIDTs provide on-the-spot results within 10-15 minutes, making them ideal for clinics, pharmacies, emergency rooms, and remote healthcare settings. The convenience of self-testing kits is also gaining traction, further fueling market growth. Compared to polymerase chain reaction (PCR) tests, RIDTs are less expensive, quicker, and easier to use, making them a preferred choice for mass screening programs and routine diagnostic use. The affordability and rapid turnaround time of RIDTs are particularly beneficial in low-resource settings, where access to laboratory-based testing is limited.
Rapid Influenza Diagnostic Tests Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.2% over the forecast period (2025-2032)
Based on Type segmentation, the influenza A segment was predicted to show maximum market share in the year 2024, due to the high need for early diagnosis.
Based on Product Type segmentation, the digital tests segment was the leading Product Type segment in 2024, with the advancement in diagnostic testing & AI solutions.
Based on End Use segmentation, the hospitals segment was the leading End Use segment in 2024, owing to the high demand for rapid diagnostics in healthcare facilities such as hospitals.
Based on the region, North America was the leading revenue generator in 2024, owing to supportive government incentives, new POC testing developments, etc.
The Global Rapid Influenza Diagnostic Tests Market is segmented based on Type, Product Type, End Use, and Region.
The market is divided into two categories based on Type: influenza A and influenza B. The influenza A segment dominates the market. The high prevalence of influenza A and the need for early diagnostic solutions are expected to bolster segment demand.
The market is divided into two categories based on the Product Type: digital diagnostic tests and conventional diagnostic tests. The digital diagnostic tests segment is expected to hold the largest share due to the higher adoption of digital platforms at hospitals for rapid influenzas diagnosis tests.
The market is divided into three categories based on End Use: hospitals, diagnostic centers, and research. The hospitals segment holds the highest share of the End Use segment. The rising prevalence of respiratory diseases and the need for hospital treatment is boosting market growth.
Rapid Influenza Diagnostic Tests Market- Geographical Insights
Across the world, the Rapid Influenza Diagnostic Tests market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America dominates the Rapid Influenza Diagnostic Tests market. This dominance is primarily due to government support for high-quality healthcare, and increased focus on influenza control. The Asia-Pacific region is emerging as the fastest-growing market for RIDTs. Factors such as increasing healthcare expenditure, rising awareness about early diagnosis and treatment of influenza, and the growing prevalence of influenza cases contribute to this growth. However, challenges such as limited access to advanced diagnostic tools and economic constraints may hinder rapid market growth in these areas.
The rapid influenza diagnostic tests market is formed by strong competition among key players. The market is experiencing robust growth, driven by technological advancements, strategic initiatives by key players, and the increasing need for rapid and accurate influenza diagnostics. The introduction of combination tests for influenza is enabling companies to develop new products. The development of tests capable of simultaneously detecting multiple respiratory pathogens, such as influenza and COVID-19, is gaining traction. These multiplex tests enhance diagnostic efficiency and patient management.
In May 2023, MaximBio secured a contract from the National Institutes of Health (NIH) to develop a new rapid test platform.
In 2024, Siemens AG introduced a new medical diagnostic solution for influenza testing to expand its product portfolio.